



(51) International Patent Classification:

C07D 487/14 (2006.01) A61P 29/00 (2006.01)
A61K 31/4985 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/EP2010/060684

(22) International Filing Date:

23 July 2010 (23.07.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/228,816 27 July 2009 (27.07.2009) US

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BILLEDEAU, Roland Joseph** [US/US]; 3491 Butcher Drive, Santa Clara, California 95051 (US).

(74) Agent: **SALUD, Carlos**; Grenzacherstrasse 124, CH-4070 Basel (CH).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) Title: TRICYCLIC INHIBITORS OF JAK



I



II

(57) Abstract: The present invention relates to the use of novel compounds of Formulae (I)-(II), wherein the variables R, X¹, X², X³, Y¹, Y², Y³, Z¹, and Z² are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.